Nurix Therapeutics (NASDAQ:NRIX) Given Overweight Rating at Stephens
Stephens restated their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $31.00 price objective on the stock. NRIX has been the subject of several other reports. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a […]
More Stories
What Battleground Voters Are Saying About Healthcare Affordability
By Lawrence Wilson “Yes, I do have opinions about this,” said Milwaukee resident Addaru Valentine just after voting in Wisconsin’s...
UAE Accuses Iran of Attacking Abu Dhabi National Oil Company Vessel in Strait of Hormuz
By Jacki Thrapp The United Arab Emirates (UAE) accused the Iranian regime of attacking an Abu Dhabi National Oil Company...
Federal Judge Declines to Block Border Wall Construction on Arizona Tribal Land
By Aldgra Fredly A federal judge on Aug. 14 refused to block the Trump administration from building a border wall...
Wall Street Review: S&P 500 Hits Record High as Inflation Cools, Earnings Stay Strong
By Panos Mourdoukoutas The S&P 500 climbed to a fresh record high this week, powered by new data showing inflation...
Fauci Refuses to Appear Before 2nd Senate Panel After Contempt Vote
By Tom Ozimek Dr. Anthony Fauci has declined a request to appear voluntarily before a second Senate panel, days after...
HHS Report on Alleged Pediatric Gender-Treatment Fraud: 5 Key Takeaways
By Stacy Robinson A report released Aug. 13 by the Department of Health and Human Services (HHS) has shined a...